Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science

Small-molecule drugs have enabled the practice of precision oncology for genetically defined patient populations since the first approval of imatinib in 2001. Scientific and technology advances over this 20-year period have driven the evolution of cancer biology, medicinal chemistry, and data scienc...

Descripción completa

Detalles Bibliográficos
Autores principales: Stuart, Darrin D., Guzman-Perez, Angel, Brooijmans, Natasja, Jackson, Erica L., Kryukov, Gregory V., Friedman, Adam A., Hoos, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551669/
https://www.ncbi.nlm.nih.gov/pubmed/37712571
http://dx.doi.org/10.1158/2159-8290.CD-23-0280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551669/
https://www.ncbi.nlm.nih.gov/pubmed/37712571
http://dx.doi.org/10.1158/2159-8290.CD-23-0280

Ejemplares similares